Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
A LupiM Senzolo

Abstract

Liver involvement is not uncommon in patients with cystic fibrosis (CF). Even if serious complications as non-cirrhotic portal hypertension, cirrhosis and liver failure rarely occur, they are associated with impaired survival and reduced quality of life. Herein, we have reported the first case of a patient with CF and non-cirrhotic portal hypertension who underwent transjugular intrahepatic portosystemic shunt placement for recurrent variceal bleeding after bilateral lung transplantation, and we have reviewed the available literature pertaining to this field.

References

Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Peter WittersDavid Cassiman
Dec 26, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Thomas Flass, Michael R Narkewicz
Apr 12, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jaclyn R StonebrakerSimon C Ling
Nov 8, 2018·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Hao WuDaniel H Leung

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.